Training activity information
Details
Perform and interpret assays for the detection of drugs of abuse in urine for the following:
- Heroin
- Morphine
- Codeine
- Methadone
- Cannabis
- Cocaine benzodiazepines (including diazepam),
- Amphetamine
- MDMA
Type
Developmental training activity (DTA)
Evidence requirements
Evidence the activity has been undertaken by the trainee.
Reflection on the activity at one or more time points after the event including learning from the activity and/or areas of the trainees practice for development.
An action plan to implement learning and/or to address skills or knowledge gaps identified.
Reflective practice guidance
The guidance below is provided to support reflection at different time points, providing you with questions to aid you to reflect for this training activity. They are provided for guidance and should not be considered as a mandatory checklist. Trainees should not be expected to provide answers to each of the guidance questions listed.
Before action
- What is the clinical of detecting these drugs of abuse in urine?
- What screening and confirmatory methods are used in your laboratory for the detection of these drugs of abuse in urine (e.g., immunoassays, chromatography-mass spectrometry)? What are the principles of these methods?
- What are the typical cut-off concentrations used for reporting positive results for each drug? What are the reasons for these cut-offs (e.g., to minimise false positives)?
- What are the potential interferences and limitations of the methods used?
- What considerations are important for sample collection and chain of custody in drugs of abuse testing, especially in settings with legal implications?
- How are the results of drugs of abuse testing interpreted in a clinical context? What factors can influence the presence and concentration of drugs in urine?
- What will you learn about the different classes of drugs of abuse, their metabolism, and their detection windows in urine?
- What challenges do you anticipate in understanding the analytical methods or interpreting discordant results?
- How will this experience enhance your ability to advise on the interpretation of common analytes in drugs of abuse screening?
- Review the Standard Operating Procedures (SOPs) for drugs of abuse testing in urine, including sample handling, screening and confirmation methods, cut-off values, and reporting guidelines.
- Read relevant literature on the pharmacology and toxicology of heroin, morphine, codeine, methadone, cannabis, cocaine, benzodiazepines, amphetamine, and MDMA, including their detection in urine.
- Familiarise yourself with the quality control procedures for these assays and the interpretation of quality control data.
- Consider potential difficulties in understanding the different analytical platforms or the clinical and legal implications of the results and think about how you might address them.
In action
- What is your involvement in performing the assays for the detection of the chosen drugs of abuse. What screening and/or confirmatory techniques are being used? What are the principles behind these methods? Why are both screening and confirmation often required?
- What decisions are you making during the analytical process? For example, how are you ensuring proper sample preparation and handling to avoid contamination or degradation? How are you operating the analysers and interpreting the raw data?
- When interpreting the results, what cut-off values are you applying for each drug? How are you differentiating between positive and negative results? What are the limitations of urine drug testing that you need to be aware of during interpretation?
- How effectively are you performing the assays? Are you encountering any issues with sensitivity, specificity, or cross-reactivity? Are the quality control samples within acceptable limits?
- When interpreting the results, how effectively are you able to identify presumptive positives on screening and confirm their presence with a secondary method (if applicable)? Are you aware of potential interferences or factors that could lead to false positive or false negative results?
- What can you learn about the practical challenges and considerations in drugs of abuse testing as the activity unfolds? How do factors like drug metabolism and detection windows influence interpretation?
- If you encounter unexpected results or discrepancies between screening and confirmation, what troubleshooting steps are you considering?
- If you are unsure about the interpretation of a particular result, especially in the context of potential legal or clinical consequences, what support or guidance might you need from senior colleagues or established protocols?
- Are you performing the assays and interpreting the results in strict accordance with the laboratory’s standard operating procedures and any relevant national or international guidelines for clinical toxicology?
On action
- Describe the assays you performed for the detection of drugs of abuse. What screening and/or confirmation methods were used? What were the results obtained for the urine samples you analysed? Were any drugs detected? How did you interpret the results, considering factors such as cut-off values and potential for false positives/negatives? What documentation and quality control procedures were followed?
- What did you learn about the principles and limitations of different methods used for drugs of abuse screening? How did this activity enhance your understanding of the interpretation of common analytes in drugs of abuse testing? Were there any challenges in performing the assays or interpreting the results? What did you learn from these?
- How will you apply your knowledge of drugs of abuse testing in your future practice? What considerations will you keep in mind regarding the interpretation of screening and confirmatory results? Are there any specific drugs or analytical techniques that you need to further understand? What resources or guidelines will you refer to for drugs of abuse testing and interpretation?
Beyond action
- Now that you have more experience with drugs of abuse testing, do you have a better understanding of the different screening and confirmation methodologies used? Reflect on any clinical you have encountered where the interpretation of these drug tests was critical. How does your initial experience relate to the broader context of drug testing? Consider if you have learned more about the metabolism and detection windows of these different drugs. Has this changed your perspective on the interpretation of results?
- Has your initial interpretation experience helped you to understand the significance of positive and negative results, as well as potential for false positives or negatives?
- Has this training activity influenced how you approach discussions about the limitations and applications of drugs of abuse screening with clinical or other staff?
- If you are involved in developing or reviewing protocols for drugs of abuse testing, how will your initial practical experience inform your contributions? Could the skills you developed in analytical sensitivity and specificity, as well as understanding legal implications, be applied to other areas of laboratory testing with similar considerations?
Relevant learning outcomes
| # | Outcome |
|---|---|
| # 1 |
Outcome
Analyse drugs, vitamins and trace elements in various biological matrices via quantitative and qualitative assays using automated and manual methodologies. |
| # 2 |
Outcome
Apply the appropriate investigative strategy to clinical situations which may involve drugs or poisons, advising clinical teams on the appropriate course of action. |
| # 3 |
Outcome
Appraise the methods in routine use for ‘drugs of abuse’ screening and advise on the interpretation of common analytes. |